Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eururo.2019.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma.
Oncologist
December 2024
Global Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ 08648, United States.
Background: Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.
Methods: We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC.
Article Synopsis
- A 75-year-old woman was referred to the hospital due to dizziness, with CT scans revealing generalized lymphadenopathy and a 10 cm tumor in her left kidney, leading to a diagnosis of Hodgkin's lymphoma and left renal cell carcinoma.
- After starting chemotherapy for the lymphoma, metastases from the renal cancer appeared after a year, prompting a shift to combination therapy with Pembrolizumab and Axitinib.
- After experiencing gastritis and severe thrombocytopenia as side effects, treatment was adjusted, and she is currently on Cabozantinib with no recurrence of previous complications.
French AFU Cancer Committee Guidelines - Update 2024-2026: Management of kidney cancer.
Fr J Urol
November 2024
Oncology Committee of the French Urology Association, Kidney Group, Maison de l'Urologie, 11, rue Viète, 75017 Paris, France; Urology, Hôpital Pitié-Salpêtrière, Predictive Onco-Urology, GRC 5, Sorbonne University, AP-HP, 75013 Paris, France.
Article Synopsis
- The objective of the study was to update recommendations for managing kidney cancer based on recent literature from 2014 to 2024, focusing on diagnosis, treatment, and follow-up methods.
- Key findings highlighted that kidney cancer linked to trichloroethylene exposure should be considered an occupational disease, and that contrast-enhanced CT scans are essential for diagnosis, while PET scans are not necessary.
- The updated guidelines recommend specific classifications for tumors, advocate for less invasive strategies like biopsies to avoid unnecessary surgeries, and suggest various surgical and treatment options tailored to tumor size, patient age, and overall health.
Osteonecrosis of the jaw in patients with clear cell renal cell carcinoma treated with targeted agents: a case series and large-scale pharmacovigilance analysis.
Front Pharmacol
October 2024
Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Objective: To optimize the use of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) for cancer patients, we characterized and evaluated ONJ related to TKIs and ICIs by analyzing a public database and reviewing the relevant literature. TKIs and ICIs are limited to drugs that treat renal cancer recommended by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Kidney Cancer.
Methods: We described a case series of patients experiencing ONJ while on TKIs or ICIs.
Pemetrexed-carboplatin salvage therapy in advanced thyroid cancers.
Head Neck
October 2024
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
Background: The overall survival of patients with advanced thyroid cancers that have progressed following targeted therapies is limited, indicating a strong need for salvage treatments.
Methods: We retrospectively analyzed patients with refractory advanced thyroid cancer treated with pemetrexed-carboplatin (PC) at Mayo Clinic since 2019.
Results: Eleven patients, three with anaplastic thyroid cancer (ATC), seven with differentiated or poorly differentiated thyroid cancer (DTC), and one with oncocytic carcinoma of the thyroid, were treated with novel salvage PC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!